{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:42:29Z","timestamp":1771479749023,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s12185-015-1746-8","type":"journal-article","created":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T05:20:51Z","timestamp":1422681651000},"page":"295-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis"],"prefix":"10.1007","volume":"101","author":[{"given":"Kenji","family":"Oritani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohshi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Gopalakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Amagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"issue":"10","key":"1746_CR1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/14656566.2011.568939","volume":"12","author":"G Barosi","year":"2011","unstructured":"Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother. 2011;12(10):1597\u2013611.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1746_CR2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","volume":"35","author":"RA Mesa","year":"2011","unstructured":"Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011;35(1):12\u20133.","journal-title":"Leuk Res"},{"issue":"13","key":"1746_CR3","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"issue":"1","key":"1746_CR4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68\u201376.","journal-title":"Cancer"},{"key":"1746_CR5","unstructured":"Kiladjian J, et al. Health-related quality of life and symptom burden in patients with myelofibrosis in the COMFORT-II study. Haematologica. 2012;97(s1) [abstract 0378]."},{"issue":"5","key":"1746_CR6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/stemcells.19-5-378","volume":"19","author":"DL Krebs","year":"2001","unstructured":"Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19(5):378\u201387.","journal-title":"Stem Cells"},{"issue":"26","key":"1746_CR7","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.2174\/092986712803251511","volume":"19","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26):4399\u2013413.","journal-title":"Curr Med Chem"},{"issue":"3","key":"1746_CR8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/ehm.10.28","volume":"3","author":"ST Oh","year":"2010","unstructured":"Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010;3(3):323\u201337.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"1746_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12185-012-1235-2","volume":"97","author":"JD Milosevic","year":"2013","unstructured":"Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2013;97(2):183\u201397.","journal-title":"Int J Hematol"},{"issue":"2","key":"1746_CR10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ajh.23384","volume":"88","author":"A Tefferi","year":"2013","unstructured":"Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(2):141\u201350.","journal-title":"Am J Hematol"},{"issue":"17","key":"1746_CR11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"4","key":"1746_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"6","key":"1746_CR13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162\u20138.","journal-title":"Blood"},{"issue":"2","key":"1746_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12185-010-0531-y","volume":"91","author":"Y Hitoshi","year":"2010","unstructured":"Hitoshi Y, Lin N, Payan DG, Markovtsov V. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol. 2010;91(2):189\u2013200.","journal-title":"Int J Hematol"},{"issue":"9","key":"1746_CR15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"9","key":"1746_CR16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"key":"1746_CR17","doi-asserted-by":"crossref","unstructured":"Verstovsek S, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood (ASH Annual Meeting Abstracts). 2013 [abstract 396].","DOI":"10.1182\/blood.V122.21.396.396"},{"issue":"25","key":"1746_CR18","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047\u201353.","journal-title":"Blood"},{"issue":"3","key":"1746_CR19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12185-013-1280-5","volume":"97","author":"Y Ogama","year":"2013","unstructured":"Ogama Y, et al. A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. Int J Hematol. 2013;97(3):351\u20139.","journal-title":"Int J Hematol"},{"key":"1746_CR20","doi-asserted-by":"crossref","unstructured":"Jung CW, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma. 2014:1\u20138. [Epub ahead of print].","DOI":"10.3109\/10428194.2014.969260"},{"issue":"5","key":"1746_CR21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"2","key":"1746_CR22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12185-010-0529-5","volume":"91","author":"M Wadleigh","year":"2010","unstructured":"Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010;91(2):174\u20139.","journal-title":"Int J Hematol"},{"issue":"2","key":"1746_CR23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437\u20138.","journal-title":"Leukemia"},{"issue":"5","key":"1746_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1746_CR25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I:\u00a0a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1746_CR26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139\u201344.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1746-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-015-1746-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1746-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T14:19:06Z","timestamp":1598710746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-015-1746-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1746-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,1]]}}}